 Christopher Schneck
Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 33 | 2026 | 278 | 6.480 |
Why?
| | Family Therapy | 19 | 2023 | 66 | 1.880 |
Why?
| | Affect | 12 | 2023 | 322 | 1.140 |
Why?
| | Telemedicine | 7 | 2025 | 960 | 0.990 |
Why?
| | Ambulatory Care Facilities | 1 | 2026 | 269 | 0.810 |
Why?
| | Mental Health Services | 5 | 2025 | 472 | 0.790 |
Why?
| | Mood Disorders | 6 | 2025 | 140 | 0.660 |
Why?
| | Estrogen Antagonists | 1 | 2020 | 37 | 0.640 |
Why?
| | Tamoxifen | 1 | 2020 | 191 | 0.600 |
Why?
| | Behavioral Symptoms | 2 | 2017 | 41 | 0.600 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2020 | 192 | 0.580 |
Why?
| | Antipsychotic Agents | 8 | 2017 | 215 | 0.410 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 4 | 2021 | 427 | 0.350 |
Why?
| | Cognition | 1 | 2020 | 1268 | 0.350 |
Why?
| | Adolescent | 26 | 2023 | 22485 | 0.320 |
Why?
| | Psychotherapy, Brief | 3 | 2020 | 41 | 0.320 |
Why?
| | Anxiety Disorders | 5 | 2021 | 370 | 0.310 |
Why?
| | Humans | 49 | 2026 | 145491 | 0.300 |
Why?
| | Algorithms | 2 | 2017 | 1855 | 0.300 |
Why?
| | Depressive Disorder | 4 | 2011 | 387 | 0.270 |
Why?
| | Family Conflict | 4 | 2022 | 43 | 0.260 |
Why?
| | Psychiatric Status Rating Scales | 5 | 2017 | 539 | 0.260 |
Why?
| | Valproic Acid | 2 | 2006 | 49 | 0.240 |
Why?
| | Depression | 5 | 2023 | 1573 | 0.230 |
Why?
| | Mental Health | 3 | 2020 | 795 | 0.220 |
Why?
| | Antimanic Agents | 2 | 2009 | 19 | 0.210 |
Why?
| | Treatment Outcome | 14 | 2023 | 11831 | 0.200 |
Why?
| | Female | 26 | 2025 | 78763 | 0.200 |
Why?
| | Anhedonia | 1 | 2023 | 18 | 0.200 |
Why?
| | Depressive Disorder, Treatment-Resistant | 1 | 2023 | 13 | 0.200 |
Why?
| | Smartphone | 1 | 2025 | 104 | 0.200 |
Why?
| | Pandemics | 3 | 2020 | 1706 | 0.200 |
Why?
| | Anticipation, Psychological | 1 | 2023 | 20 | 0.190 |
Why?
| | Family Relations | 3 | 2020 | 88 | 0.190 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6070 | 0.190 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2002 | 30 | 0.180 |
Why?
| | Ketamine | 1 | 2023 | 137 | 0.180 |
Why?
| | Comorbidity | 4 | 2019 | 1659 | 0.180 |
Why?
| | Child | 11 | 2022 | 22680 | 0.180 |
Why?
| | Age of Onset | 4 | 2011 | 554 | 0.170 |
Why?
| | Patient Education as Topic | 5 | 2017 | 775 | 0.170 |
Why?
| | Nucleus Accumbens | 1 | 2023 | 135 | 0.170 |
Why?
| | Amygdala | 1 | 2023 | 199 | 0.170 |
Why?
| | Antidepressive Agents | 3 | 2009 | 250 | 0.170 |
Why?
| | Language | 1 | 2024 | 323 | 0.160 |
Why?
| | Reward | 1 | 2023 | 249 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2024 | 368 | 0.160 |
Why?
| | Feedback | 1 | 2020 | 181 | 0.150 |
Why?
| | Decision Support Systems, Clinical | 1 | 2024 | 271 | 0.150 |
Why?
| | Male | 22 | 2025 | 72817 | 0.150 |
Why?
| | Combined Modality Therapy | 5 | 2023 | 1269 | 0.150 |
Why?
| | Ericales | 1 | 1998 | 2 | 0.150 |
Why?
| | Panic Disorder | 1 | 1998 | 22 | 0.140 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 56 | 0.140 |
Why?
| | Phytotherapy | 1 | 1998 | 74 | 0.140 |
Why?
| | Outpatients | 2 | 2020 | 447 | 0.140 |
Why?
| | Psychiatry | 1 | 2020 | 196 | 0.130 |
Why?
| | House Calls | 1 | 2019 | 154 | 0.130 |
Why?
| | Suicidal Ideation | 2 | 2020 | 577 | 0.130 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 232 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 600 | 0.130 |
Why?
| | Kidney Transplantation | 1 | 2023 | 711 | 0.120 |
Why?
| | Drug Monitoring | 1 | 2019 | 400 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2020 | 608 | 0.120 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 590 | 0.110 |
Why?
| | Mental Disorders | 2 | 2025 | 1157 | 0.110 |
Why?
| | Movement Disorders | 1 | 2015 | 70 | 0.110 |
Why?
| | Irritable Mood | 2 | 2019 | 50 | 0.110 |
Why?
| | Psychotropic Drugs | 4 | 2020 | 78 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2023 | 1153 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 884 | 0.100 |
Why?
| | Expressed Emotion | 2 | 2013 | 15 | 0.100 |
Why?
| | Adult | 7 | 2025 | 40707 | 0.100 |
Why?
| | Risk Factors | 5 | 2013 | 10874 | 0.100 |
Why?
| | Diagnosis, Differential | 2 | 2009 | 1507 | 0.090 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 908 | 0.090 |
Why?
| | Psychotherapy | 2 | 2019 | 190 | 0.080 |
Why?
| | Sex Factors | 2 | 2009 | 2110 | 0.080 |
Why?
| | Risk Assessment | 2 | 2017 | 3759 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2011 | 2945 | 0.080 |
Why?
| | Euphoria | 1 | 2009 | 2 | 0.070 |
Why?
| | Hostility | 1 | 2009 | 16 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3157 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2020 | 17269 | 0.070 |
Why?
| | Disease Progression | 2 | 2020 | 2862 | 0.070 |
Why?
| | Thinking | 1 | 2009 | 66 | 0.070 |
Why?
| | Quality of Life | 2 | 2019 | 3195 | 0.070 |
Why?
| | Problem Solving | 3 | 2017 | 158 | 0.070 |
Why?
| | Anticonvulsants | 2 | 2008 | 246 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2009 | 1046 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2008 | 256 | 0.060 |
Why?
| | Lithium Compounds | 1 | 2006 | 11 | 0.060 |
Why?
| | Models, Psychological | 1 | 2008 | 297 | 0.060 |
Why?
| | Patient Care Management | 1 | 2006 | 56 | 0.060 |
Why?
| | Cohort Studies | 2 | 2008 | 5992 | 0.060 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2004 | 39 | 0.050 |
Why?
| | Critical Pathways | 1 | 2006 | 108 | 0.050 |
Why?
| | Prospective Studies | 2 | 2008 | 8039 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3189 | 0.050 |
Why?
| | Motor Activity | 1 | 2009 | 723 | 0.050 |
Why?
| | Lithium | 1 | 2023 | 40 | 0.050 |
Why?
| | Anxiety | 2 | 2021 | 1127 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 427 | 0.050 |
Why?
| | Communication | 3 | 2017 | 975 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2023 | 243 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2009 | 5426 | 0.040 |
Why?
| | Waiting Lists | 1 | 2023 | 266 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5891 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 456 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 282 | 0.040 |
Why?
| | Age Factors | 1 | 2008 | 3340 | 0.040 |
Why?
| | Family Health | 2 | 2013 | 191 | 0.040 |
Why?
| | Psychomotor Agitation | 1 | 2019 | 70 | 0.040 |
Why?
| | Middle Aged | 4 | 2025 | 36176 | 0.040 |
Why?
| | Food, Organic | 1 | 1998 | 2 | 0.040 |
Why?
| | Sertraline | 1 | 1998 | 27 | 0.040 |
Why?
| | Executive Function | 1 | 2023 | 469 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1139 | 0.040 |
Why?
| | Organophosphates | 1 | 2019 | 179 | 0.030 |
Why?
| | Animals | 1 | 2020 | 38141 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2019 | 445 | 0.030 |
Why?
| | Prodromal Symptoms | 1 | 2017 | 20 | 0.030 |
Why?
| | Prevalence | 1 | 2004 | 2855 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 528 | 0.030 |
Why?
| | Adenine | 1 | 2019 | 338 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2018 | 132 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2950 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2019 | 566 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 1119 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1001 | 0.030 |
Why?
| | Patient Compliance | 2 | 2011 | 587 | 0.030 |
Why?
| | Mothers | 1 | 2021 | 767 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2004 | 1097 | 0.030 |
Why?
| | Videoconferencing | 1 | 2015 | 65 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1896 | 0.030 |
Why?
| | Emotions | 1 | 2018 | 579 | 0.020 |
Why?
| | Early Medical Intervention | 1 | 2013 | 62 | 0.020 |
Why?
| | Research | 1 | 2015 | 432 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3424 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1369 | 0.020 |
Why?
| | Parents | 1 | 2020 | 1404 | 0.020 |
Why?
| | Education | 1 | 2009 | 105 | 0.020 |
Why?
| | Convalescence | 1 | 2008 | 19 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4283 | 0.020 |
Why?
| | Young Adult | 1 | 2023 | 14192 | 0.010 |
Why?
| | Recurrence | 1 | 2008 | 1142 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 7171 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 2355 | 0.010 |
Why?
| | Adolescent Behavior | 1 | 2004 | 497 | 0.010 |
Why?
|
|
Schneck's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|